Chinese researchers found that type 2 diabetes patients taking metformin – one of the first lines of defense in the treatment of the disease - attained a better overall lipid profile compared with those who took glipizide.
A new wound-care dressing developed by a California firm has been shown to not only reduce the cost of treating wounds, but also to improve the outcomes of those treatments.
That’s good news for diabetics. According to statistics, about 15 percent of those with the disease develop chronic wounds – most often foot ulcers – that can result in amputation.
The was study, conducted at the Southwest Regional Wound Care Center in Lubbock, Texas. They found, Enluxtra Any Wound dressing developed by OSNovative Systems, Inc., reduced medical costs of chronic wound care by 30 percent. In part because it replaces many different products. Including primary foam, the gelling agent alginate, hydrogel dressings, hydro-conductive fiber, super-absorbent collagen, opaque dressing, hydrocolloid, gauze and combination dressings.
Any Wound dressing, crafted of FDA-approved polymers, is designed to sense and accommodate the different parts of the wound that need hydration or absorption, and a single dressing can remain in place for up to seven days.
Tandem is in partnership with the JDRF to develop a dual hormone pump which will continue to be funded, as Tandem reaches different milestones. Once approved by the FDA, this novel and groundbreaking medical device will have two hormone chambers. One chamber for insulin, the second chamber for a different hormone that supports different therapies. “At this time, insulin is the only approved hormone for an insulin pump,” says Susan Morrison, Chief Administrative Officer from Tandem Diabetes Care.
When news about a startling new insight into the cause of Alzheimer's disease first emerged in 2005, it was highly speculative. But now the evidence for it has become very strong: Alzheimer's is a form of diabetes, and the name being given to it is type 3.
All Dr. Christopher Jacobs’ friend wanted a lancing device that didn’t cause pain. And after hearing the longtime type 1 diabetic lament the discomfort he felt from the many finger pricks required to test his blood glucose levels, Jacobs was intrigued by the challenge.
An Italian-based pharmaceutical company with subsidiaries in New York has been granted orphan drug status for a new drug to treat neurotrophic keratitis, a rare degenerative corneal disease that impacts less than 1 in 5,000 people worldwide.
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.